ARHGEF19

Across TCGA pan-cancer cohorts, ARHGEF19 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF19 data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ARHGEF19 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARHGEF19 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

OV, UCEC, and LIHC are the cancer types where ARHGEF19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.147	0.542	<.001	18	view →
UCEC	DFS	Median	All	0.967	0.829	.027	10	view →
LIHC	OS	Median	All	0.105	0.777	<.001	9	view →
HNSC	OS	Median	All	0.268	0.713	.011	6	view →
SKCM	OS	Median	II,III,IV	1.000	0.725	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGEF19–OV (DFS)

Open the OV breakdown →